Publicaciones

Año 2021

• Solís O, García-Sanz P, Martín AB, Granado N, Sanz-Magro A, Podlesniy P, Trullas R, Murer MG, Maldonado R, Moratalla R. Behavioral sensitization and cellular responses to psychostimulants are reduced in D2R knockout mice. Addict Biol. 2021;26(1):e12840. doi: 10.1111/adb.12840. IF:4.12
• Serrano A, Vadas E, Ferrer B, Bilbao A, Granado N, Suárez J, Pavon FJ, Moratalla R, Rodríguez de Fonseca F. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210. Psychopharmacology (Berl). 2021;238:551-557. IF: 3.13.

Año 2020

• Alberquilla S, Gonzalez-Granillo A, Martín ED, Moratalla R. Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner Neurobiol Dis. 2020 Feb;134:104666. doi: 10.1016/j.nbd.2019.104666. IF:5.33
• Barroso-Chinea P, Luis-Ravelo D, Fumagallo-Reading F, Castro-Hernandez J, Salas-Hernandez J, Rodriguez-Nuñez J, Febles-Casquero A, Cruz-Muros I, Afonso-Oramas D, Abreu-Gonzalez P, Moratalla R, Millan MJ, Gonzalez-Hernandez T. DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis. Autophagy. 2020. 16:1279-1295. doi: 10.1080/15548627.2019.1668606. IF:9.77
• Rodríguez-Traver E, Díaz-Guerra E, Rodríguez C, Fernández P, Arenas F, Araúzo-Bravo M, Orera M, Kulisevsky J, Moratalla R, Vicario C. A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene. Stem Cell Res. 2020 Jan;42:101663. doi: 10.1016/j.scr.2019.101663.IF:4.49
• Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, Moratalla R. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Neurobiol Dis. 2020 Jul;141:104892. doi: 10.1016/j.nbd.2020.104892. IF:5.33
• Gómez-Benito M, Granado N, García-Sanz P, Dumoulin M, and Moratalla R. Modeling Parkinson’s disease with the alpha-synuclein protein. Front Pharmacol. 2020 Apr 23;11:356. doi: 10.3389/fphar.2020.00356. eCollection 2020. IF: 4.22
• Suarez LM, Solís O, Sanz-Magro A, Alberquilla S, and Moratalla R. D1 receptor regulates spine density in direct and indirect striatal projection neurons. Mov Disord. 2020;35:1810-1821. doi: 10.1002/mds.28174.. IF: 8.68
• Pérez-Taboada I, Alberquilla S, Martín ED, Anand R, Vietti-Michelina S, Tebeka NN, Cantley J, Cragg SJ, Moratalla R, Vallejo M. Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice. Mov Disord. 2020;35:1636-1648. doi: 10.1002/mds.28124. IF: 8.68.
• Rivera P, Aranda J, Alén F, Vargas A, Serrano A, Pavón FJ, Orio L, Rubio L, Moratalla R, Rodríguez de Fonseca F, Suárez J. Sex-specific behavioral and neurogenic responses to cocaine in mice lacking and blocking dopamine D1 or dopamine D2 receptors. J Comp Neurol. 2020. doi: 10.1002/cne.25052. IF: 2.81
• García-Sanz P, Aerts J M F G, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2020. Nov 21. doi: 10.1002/mds.28396. IF: 8.68.
• Espadas I, Ortiz O, García-Sanz P, Sanz-Magro A, Alberquilla S, Solis O, Delgado-García JM, Gruart A, Moratalla R. Dopamine D2R is Required for Hippocampal-dependent Memory and Plasticity at the CA3-CA1 Synapse. Cereb Cortex. 2020 Dec 3:bhaa354. doi: 10.1093/cercor/bhaa354. IF: 5.04

Año 2019

• García-Montes JR, Solís O, Enríquez-Traba J, Ruiz-DeDiego I, Drucker-Colín R, Moratalla R. Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice. Mol Neurobiol. 2019;56:4037-4050. doi: 10.1007/s12035-018-1356-6.. IF: 5.07
• Del Río-Martín A, Pérez-Taboada I, Fernández-Pérez A, Moratalla R, de la Villa P, Vallejo M. Hypomorphic Expression of Pitx3 Disrupts Circadian Clocks and Prevents Metabolic Entrainment of Energy Expenditure. Cell Rep. 2019.29:3678-3692.e4. doi: 10.1016/j.celrep.2019.11.027. IF:8.11
• Gomez G, Escande MV, Suarez LM, Rela L, Belforte JE, Moratalla R, Murer MG, Gershanik OS, Taravini IRE. Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in L-Dopa-Induced Dyskinesia. Mol Neurobiol. 2019;56:6261-6275. doi: 10.1007/s12035-019-1515-4. IF:5.07
• Keifman E, Ruiz de Diego I, Pafundo DE, Paz RM, Solís O, Murer MG, Moratalla R. Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease. Br J Pharmacol. 2019;176:2146-2161. doi: 10.1111/bph.14663.. IF:7.73
• Rodríguez-Traver E, Rodríguez C, Díaz-Guerra E, Arenas F, Araúzo-Bravo M, Orera M, Kulisevsky J, Moratalla R, Vicario C. Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene. Stem Cell Res. 2019. 40:101578. doi: 10.1016/j.scr.2019.101578. IF:4.49

Año 2018

• García-Sanz P and Moratalla R. The importance of colesterol accumulation in Parkinson’s disease, Mov Disord. 2018, DOI 10.1002/mds.27251, IF=7.01
• García-Sanz P, Orgaz L, Fuentes JM, Mir P, Vicario C and Moratalla R. Cholesterol and multilamellar bodies: Lyosomal dysfunction in GBA-Parkinson disease. Autophagy 2018, DOI 10.1080/15548627.2018.1427396, IF=8.01

Año 2017

• Solís O, Garcia-Montes JR, González-Granillo A, Xu M, Moratalla R. Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb Cortex. 2017. 27: 435–446. IF=8.66
• Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol. 2017. 155:149-170, IF=9.99
• García-Sanz P, Mirasierra M, Moratalla R, Vallejo M. Embryonic defence mechanisms against glucose-dependent oxidative stress require enhanced expression of Alx3 to prevent malformations during diabetic pregnancy. Scientific Reports. 2017. 7:389. IF=5.22
• Solís O, Garcia-Montes JR, Garcia-Sanz P, Herranz AS, Asensio MA, Kang G, Hiroi N, Moratalla R. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. Neurobiology of Disease. 2017. 102: 133-139 IF=4.85
• F Hernández L, Castela I, Ruiz-DeDiego I, Obeso JA, Moratalla R. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. Mov Disord. 2017. 32: 530-537. IF=7.01
• García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, Gutierrez A, Dávila JC, González-Polo RA, Fuentes JM, Mir P, Vicario C, Moratalla R. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Mov Disord. 2017 doi: 10.1002/mds.27119. IF=7.01

Año 2016

• Suarez LM, Solis O, Aguado C, Lujan R, Moratalla R. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia. Cereb Cortex.2016. IF=8.66
• Rodríguez-Traver E, Solís O, Díaz-Guerra E, Ortiz Ó, Vergaño-Vera E, Méndez-Gómez HR, García-Sanz P, Moratalla R, Vicario-Abejón C. Role of nurr1 in the generation and differentiation of dopaminergic neurons from stem cells. Neurotox Res. 2016. 30:14-31. doi: 10.1007/s12640-015-9586-0 IF=3.538
• Solís O, García-Sanz P, Herranz AS, Asensio MJ, Moratalla R. L-DOPA reverses the increased free amino acids tissue levels induced by dopamine depletion and rises GABA and tyrosine in the striatum. Neurotox Res. 2016. 30:67-75. doi: 10.1007/s12640-016-9612-x. IF=3.538
• Mendieta L, Granado N, Aguilera J, Tizabi Y, Moratalla R. Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice. Int J Neuropsychopharmacol. 2016. pii: pyw021 IF=4.33

Año 2015

• Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo JR, Moratalla R. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry. 2015. 77:95-105. IF=10.255
• Solis O, Espadas I, Del-Bel EA, Moratalla R. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice. Neurobiol Dis. 2015. 73:49-59. IF=5.078
• Vergaño-Vera E, Díaz-Guerra E, Rodríguez-Traver E, Méndez-Gómez HR, Solís O, Pignatelli J, Pickel J, Lee SH, Moratalla R, Vicario-Abejón C. Nurr1 blocks the mitogenic effect of FGF-2 and EGF, inducing olfactory bulb neural stem cells to adopt dopaminergic and dopaminergic-GABAergic neuronal phenotypes. Dev Neurobiol. 2015. 75:823-41. IF=3.370
• Carmena A, Granado N, Ares-Santos S, Alberquilla S, Tizabi Y, Moratalla R. Methamphetamine-induced toxicity in indusium griseum of mice is associated with astro- and microgliosis. Neurotox Res. 2015. 27:209-16. IF= 3.538
• Castro-Hernández J, Afonso-Oramas D, Cruz-Muros I, Salas-Hernández J, Barroso-Chinea P, Moratalla R, Millan MJ, González-Hernández T. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Neurobiol Dis. 2015. 74:325-35. IF= 5.078
• Ruiz-DeDiego I, Naranjo JR, Hervé D, Moratalla R. Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum. Mov Disord. 2015. 30:1039-49. IF= 5.680
• Martín R, Bajo-Grañeras R, Moratalla R, Perea G, Araque A. Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. Science. 2015. 349:730-734. IF=33.61

Año 2014

• Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 2014. 75:711-22. IF=10.255
• Urrutia A, Granado N, Gutierrez-Lopez MD, Moratalla R, O'Shea E, Colado MI. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum. Int J Neuropsychopharmacol. 2014. 17:235-46. IF=4.009
• Gonzalez-Aparicio R and Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease. Neurobiol Dis. 2014. 62:416-25. IF=5.078
• Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology. 2014. 39:1066-80. IF=7.048
• Granado N, Ares-Santos S, Moratalla R. D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice. Neurotox Res. 2014. 25:100-9. IF=3.538
• Shen HY, Canas PM, Garcia-Sanz P, Lan JQ, Boison D, Moratalla R, Cunha RA, Chen JF. Adenosine A2A receptor in striatal glutamatergic terminal and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One. 2013. 8:e80902. IF=3.534
• Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, Granado N, Moratalla R, Labandeira-Garcia JL. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging. 2014. 35:1726-38. IF= 5.013
• Heumann R, Moratalla R, Herrero MT, Chakrabarty K, Drucker-Colín R, Garcia-Montes JR, Simola N, Morelli M. Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. J Neurochem. 2014. 130:472-89. IF=4.281

Año 2013

• Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R. L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2-Expressing Projection Neurons in Dyskinetic Mice. Biol Psychiatry. 2013 Jun 12. pii: S0006-3223(13)00416-2. doi: 10.1016/j.biopsych.2013.05.006. IF=9.24
• González-Aparicio R, Moratalla R.Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease. Neurobiol Dis. 2014 Feb;62:416-25. doi: 10.1016/j.nbd.2013.10.008. IF=5.63
• Shen HY, Canas PM, Garcia-Sanz P, Lan JQ, Boison D, Moratalla R, Cunha RA, Chen JF. Adenosine A2A Receptors in Striatal Glutamatergic Terminals and GABAergic Neurons Oppositely Modulate Psychostimulant Action and DARPP-32 Phosphorylation. PLoS One. 2013 Nov 28;8(11):e80902. doi: 10.1371/journal.pone.0080902. eCollection 2013. IF=4,09
• López-Jiménez A, Walter NA, Giné E, Santos Á, Echeverry-Alzate V, Bühler KM, Olmos P, Giezendanner S, Moratalla R, Montoliu L, Buck KJ, López-Moreno JA. A spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption. Synapse. 2013 Jun;67(6):280-9. doi: 10.1002/syn.21639. IF=2.95
• Ares-Santos S, Granado N, Moratalla R.The role of dopamine receptors in the neurotoxicity of methamphetamine. J Intern Med. 2013 May;273(5):437-53. doi: 10.1111/joim.12049. Review. IF=5.48
• Granado N, Ares-Santos S, Moratalla R. (2013) Methamphetamine and Parkinson's disease. Parkinsons Dis.;2013:308052. doi: 10.1155/2013/308052. Epub 2013 Feb 7. IF=1.08
• Peraile I, Granado N, Torres E, Gutiérrez-López MD, Moratalla R, Colado MI, O'Shea E. Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical-induced neurodegenerative disorders. Psychopharmacology (Berl). 2013 Nov;230(1):125-35. doi: 10.1007/s00213-013-3142-5. IF=4,08
• Hai-Ying S, Canas PM, Garcia-Sanz P, Boison D, Moratalla R, Cunha RA, Chen JF. (2013) Adenosine A2A receptor in striatal glutamatergic terminal and GABAergic neuron oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One, en prensa IF=4.09
• Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R. (2013) L-DOPA treatment selectively restores spine density in D2R-expressing projection neurons in dyskinetic mice. Biological Psychiatry, aceptado (PBS-114848) IF=9.24
• Gonzalez-Aparicio R, Moratalla R. (2013) Oleoylethanolamide reduces L-Dopa-induced dyskinesias via TRPV1 receptor in a mouse model of Parkinson´s Disease. Neuorol Dis,. IF=5.63
• Urritia A, Granado N, Gutierrez-Lopez MD, Moratalla R, O'Shea E, Colado M. (2013) The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum. Int J Neuropsychopharmacol, en prensa. IF=5.64
• Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. Methamphetamine Causes Degeneration of Dopamine Cell Bodies and Terminals of the Nigrostriatal Pathway Evidenced by Silver Staining. Neuropsychopharmacology. 2013 Oct 30. doi: 10.1038/npp.2013.307. [Epub ahead of print] IF=8.67

Año 2012

• Ares-Santos S, Granado N, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R. (2012) Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis. 45:810-820 IF=5.63
• Madronal N, Gruart A, Valverde O, Espadas I, Moratalla R, Delgado-Garcia JM. (2012) Involvement of cannabinoid CB1 receptor in associative learning and in hippocampal CA3-CA1 synaptic plasticity. Cerebral Cortex; 22:550-556 IF=6.84
• Espadas I, Darmopil S, Vergaño-Vera E, Ortiz O, Oliva I, Vicario-Abejón C, Martín ED, Moratalla R. (2012) L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function. Neurobiol Dis.; 48:271-81 IF=5.63
• Busceti CL, Bucci D, Molinaro G, Di Pietro P, Zangrandi L, Gradini R, Moratalla R, Battaglia G, Bruno V, Nicoletti F, Fornai F. (2012) Lack or inhibition of dopaminergic stimulation induces a development increase of striatal tyrosine hydroxylase-positive interneurons. PLoS One;7:e44025. doi: 10.1371/journal.pone.0044025. Epub 2012 Sep 18. IF=4.09

Año 2011

• Suárez J, Ortiz O, Puente N, Bermúdez-Silva FJ, Blanco E, Fernández-Llebrez P, Grandes P, de Fonseca FR, Moratalla R. (2011) Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience, 192:112-31. IF=3,22
• Murer MG, Moratalla R. (2011) Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation. Front Neuroanat.; 5:51.
• Antonelli MC, Guillemin GJ, Raisman-Vozari R, Del-Bel EA, Aschner M, Collins MA, Tizabi Y, Moratalla R, West AK. (2011) New Strategies in Neuroprotection and Neurorepair. Neurotox Res.; 21:49-56 IF=3,02
• Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R. (2011)Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis., 42:391-403. IF=5,63
• Moreno E, Hoffmann H, Gonzalez-Sepúlveda M, Navarro G, Casadó V, Cortés A, Mallol J, Vignes M, McCormick PJ, Canela EI, Lluís C, Moratalla R, Ferré S, Ortiz J, Franco R. (2011) Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem.; 286:5846-54. IF=5,33
• Johnson PL, Fitz S, Hollis J, Moratalla R, Lightman SL, Shekhar A, Lowry CA. (2011) Induction of c-Fos in “panic/defense”-related brain circuits following brief hypercarbic gas exposure. J Psychopharmacol,; 25:26-36. IF= 4,06
• Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado A, Moratalla R. (2011) Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia, 59:1850-63 IF=5.19
• Méndez-Gómez HR, Vergaño-Vera E, Abad JL, Bulfone A, Moratalla R, de Pablo F, Vicario-Abejón C. (2011) The T-box brain 1 (Tbr1) transcription factor inhibits astrocyte formation in the olfactory bulb and regulates neural stem cell fate. Mol Cell Neurosci.; 46:108-21 IF=3.86

Año 2010

• Granado N, Ares-Santos S, O'Shea E, Vicario-Abejón C, Colado MI, Moratalla R. (2010). Pubmed_DefaultReportPanel.Pubmed_RVDocSum" Selective Vulnerability in Striosomes and in the Nigrostriatal Dopaminergic Pathway After Methamphetamine Administration: Early Loss of TH in Striosomes After Methamphetamine. Neurotox Res., 18: 48-58. IF=3,02
• Ramiro-Fuentes S, Ortiz O, Moratalla R, and E Fernandez-Espejo. (2010) Intra-accumbal rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo CB1R silencing: critical role for glutamate receptors. Neuroscience, 167:205-215. IF=3,22
• Gramage E, Rossi L, Granado N, Moratalla R, Herradón G. (2010) Genetic inactivation of pleiotrophin triggers amphetamine-induced cell loss in the substantia nigra and enhances amphetamine neurotoxicity in the striatum. Neuroscience, 170: 308-316. IF=3,22
• Ortiz O, Delgado-García JM, Espadas I, Dreyer JL, Bahí A, Trullas R, Gruart A and R Moratalla. (2010) Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null mice and hippocampal siRNA silenced D1R mice. J Neurosci, 30:12288-12300, IF= 7,8

Publicaciones mas relevantes